ProSciento
ProSciento is a private, metabolic disease-focused contract research organization founded in 2003 that delivers full-service clinical trial execution, regulatory strategy, and early-phase clinical research to pharmaceutical and biotechnology sponsors developing therapeutics across the metabolic continuum.
- Company typePrivate
- Founded2003
- HeadquartersChula Vista, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What ProSciento does
ProSciento, Inc. is a private, founder-controlled contract research organization (CRO) founded in 2003 by physician-scientist Marcus Hompesch, MD, and headquartered in Chula Vista, California. The company is purpose-built exclusively for clinical research across the metabolic continuum — spanning diabetes, obesity, MASLD/MASH, cardiovascular disease, and chronic kidney disease — and serves pharmaceutical and biotechnology sponsors developing metabolic therapeutics, as well as academic and research institutions seeking specialized metabolic infrastructure.
The company delivers its offering through five integrated service modules: Contract Research Organization (CRO) for global full-service trial execution; Clinical and Regulatory Development (CRD) for early-stage scientific and regulatory strategy; a 30,000 sq ft in-house Clinical Research Unit (CRU) with 30+ beds, 15+ glucose clamp beds, and a CLIA-certified laboratory for first-in-human through early-phase studies; Participant and Site Support (PSS) anchored by a proprietary database of 180,000+ metabolically characterized participants; and Clinical Research Innovation (CRI), through which ProSciento contributes peer-reviewed publications, editorial leadership of the journal Endocrinology, Diabetes & Metabolism, and co-authorship of a recognized clinical research textbook. The technical platform spans a 250+ site global clinical network, 55 method hubs, and a proprietary telehealth recruitment and pre-screening platform.
Commercially, ProSciento operates a B2B enterprise sales model targeting pharma and biotech sponsors, with engagements structured as multi-year professional services contracts negotiated on a per-program basis and delivered through a single integrated point of contact spanning feasibility through Phase 3. The company has supported 175+ FDA submissions and 20 approved therapeutics, with European operations conducted through wholly-owned subsidiary ProSciento Europe B.V. in Maastricht, the Netherlands, for EU regulatory and GDPR purposes. Ownership remains concentrated with the founder (who serves as CEO and Chairman), and no external institutional funding rounds have been identified in available sources.
ProSciento firmographics
Firmographics- Name
- ProSciento
- Legal name
- ProSciento, Inc.
- Website
- https://prosciento.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- ProSciento is a private, metabolic disease-focused contract research organization founded in 2003 that delivers full-service clinical trial execution, regulatory strategy, and early-phase clinical research to pharmaceutical and biotechnology sponsors developing therapeutics across the metabolic continuum.
- Ownership category
- akta.pro rank
ProSciento industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)
Keywords
Where ProSciento is headquartered
LocationHeadquarters
- HQ city
- Chula Vista
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
ProSciento business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Clinical Research Services (CRO/CRD/PSS/CRI): ProSciento generates revenue through full-service clinical research organization (CRO) engagements, clinical and regulatory development consulting, clinical research unit (CRU) operations, participant and site support services, and clinical research innovation contributions. Services span from early scientific and regulatory strategy through Phase 3 clinical trial execution, delivered globally through a single integrated point of contact across a network of 250+ clinical sites. Revenue is contract-based, typically multi-year clinical development agreements with pharmaceutical and life sciences sponsors.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
ProSciento product offering
Product offeringCore offering
ProSciento is a specialized contract research organization (CRO) built around the metabolic disease continuum, providing full-service clinical trial execution from early scientific strategy through Phase 3. Services span Contract Research Organization (CRO) execution, Clinical and Regulatory Development (CRD), a dedicated Clinical Research Unit (CRU) for early-phase studies, Participant and Site Support (PSS) using a proprietary 180,000+ participant database, and Clinical Research Innovation (CRI). The company serves pharmaceutical and biotechnology sponsors across diabetes, obesity, MASLD/MASH, cardiovascular disease, and chronic kidney disease indications.
Product overview
ProSciento is a specialized Contract Research Organization (CRO) built around the metabolic continuum, offering five integrated service modules: Contract Research Organization (CRO) for global clinical trial execution, Clinical and Regulatory Development (CRD) for early-stage scientific and regulatory strategy, Clinical Research Unit (CRU) featuring an in-house 30,000 sq ft early-phase research facility, Participant and Site Support (PSS) leveraging a proprietary database of 180,000+ participants, and Clinical Research Innovation (CRI) for scientific research and publication. These five modules work as an integrated full-service CRO supporting every stage of clinical development from first-in-human studies through Phase 3.
Differentiator
Problem solved
Functional benefit
Products and services
- Contract Research Organization (CRO) Full-service global clinical trial execution for pharmaceutical and biotech sponsors developing metabolic disease therapeutics, delivered across a network of 250+ clinical sites with deep metabolic expertise embedded at every level. Supports regulatory affairs, medical writing, feasibility, site selection, clinical and project management, data management, and pharmacovigilance through a single integrated point of contact from startup through completion.
- Clinical and Regulatory Development (CRD) Scientific and regulatory strategy services for the earliest stages of metabolic disease clinical development. Engages with sponsors at program inception to clarify the science, strategy, and regulatory pathway before formal program launch. Includes regulatory affairs support, medical writing, feasibility, site selection, clinical and project management, data management, pharmacovigilance, and medical monitoring.
- Clinical Research Unit (CRU) State-of-the-art in-house early-phase metabolic research facility in Chula Vista, California: a 30,000 sq ft dedicated unit with 30+ beds, 15+ glucose clamp beds, a CLIA-certified laboratory, and 24/7 on-site medical and clinical teams. Designed for first-in-human through early-phase metabolic disease studies, providing academic-level sophistication in a dedicated private research setting with direct participant access and faster startup.
- Participant and Site Support (PSS) Relationship-centered participant and site engagement service leveraging a proprietary database of 180,000+ participants each with 200+ metabolic characterization data points. Provides exceptional visibility into participant populations across the metabolic continuum for more informed feasibility assessments, more reliable enrollment planning, and stronger retention throughout clinical studies.
- Clinical Research Innovation (CRI) Scientific research and publication service contributing to metabolic disease science through peer-reviewed publications, translational research, editorial leadership of an international scientific journal (Endocrinology, Diabetes & Metabolism), and co-authorship of a widely recognized textbook in the field. Insights from CRI flow directly into study design and execution for clients.
Quantifiable outcome
- 180,000+ participants in proprietary database with 200+ metabolic characterization data points
- +4 more outcomes
Companies that use ProSciento
Customer profileSegments2 records
Ideal customer profiles2 records
ProSciento technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
ProSciento partnerships and signals
Strategic signalScale indicators9 records
Recent moves6 records
Expansion highlights5 records
ProSciento competitors and assessment
Company assessmentOthers
Direct peers
- Medpace: Mid-sized, therapeutically focused full-service CRO with strong scientific expertise. Like ProSciento, Medpace differentiates on quality and therapeutic specialization rather than scale, and has demonstrated strong growth and profitability as a mid-sized alternative to global CROs.
- Profil Institut für Stoffwechselforschung: Specialized metabolic disease CRO headquartered in Germany, founded by the same research lineage as ProSciento (Marcus Hompesch was previously COO at Profil). Profil focuses on diabetes and obesity clinical research with deep metabolic expertise directly comparable to ProSciento.
- Celerion: Early-phase clinical research CRO specializing in first-in-human through Phase 2a studies, with particular strength in metabolic, cardiovascular, and respiratory research. Celerion's early-phase focus and metabolic disease capabilities make it a direct competitor for ProSciento's CRU-based Phase 1 services.
- Worldwide Clinical Trials: Mid-sized specialty CRO with deep expertise in metabolically related indications (cardiometabolic, CNS, rare disease). Similar in scale and therapeutic specialization approach to ProSciento, with comparable full-service Phase 1-3 capabilities.
- QPS Holdings: Early-phase CRO with strong metabolic disease, neuroscience, and translational research capabilities. Operates Phase 1 clinical research units and bioanalytical laboratories comparable to ProSciento's CRU and CLIA-certified lab offerings.
- Biotrial: European-headquartered early-phase clinical research organization with strong metabolic and neurology expertise. Operates dedicated Phase 1 units in Europe and North America, competing with ProSciento for early-phase metabolic trials with European sponsors.
Broad incumbents
- IQVIA: Largest global full-service CRO offering end-to-end clinical development services across all therapeutic areas, including metabolic disease. Represents the scale competitor that can bundle multiple indications and offer global site networks beyond ProSciento's specialty positioning.
- Labcorp Drug Development (Fortrea): Fortrea, spun off from Labcorp, is a major global CRO with extensive metabolic and central laboratory capabilities. Its CLIA-certified central labs and global site network make it a direct competitor for integrated CRO + central lab services.
- Syneos Health: Global biopharmaceutical solutions organization offering clinical development and commercialization services across therapeutic areas. Following its 2023 take-private transaction, Syneos competes with ProSciento for mid-to-large metabolic clinical development programs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ProSciento social profiles
Digital presenceProSciento financial estimates
Financial estimateRevenue estimate
Valuation estimate
ProSciento leadership team
Management profileNumber of profiles
Profiles8 records
ProSciento subsidiaries and ownership
Company hierarchySubsidiaries1 record
ProSciento funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ProSciento M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ProSciento
What does ProSciento do?
ProSciento is a specialized contract research organization (CRO) built around the metabolic disease continuum, providing full-service clinical trial execution from early scientific strategy through Phase 3. Services span Contract Research Organization (CRO) execution, Clinical and Regulatory Development (CRD), a dedicated Clinical Research Unit (CRU) for early-phase studies, Participant and Site Support (PSS) using a proprietary 180,000+ participant database, and Clinical Research Innovation (CRI). The company serves pharmaceutical and biotechnology sponsors across diabetes, obesity, MASLD/MASH, cardiovascular disease, and chronic kidney disease indications.
Is ProSciento a public or private company?
ProSciento is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ProSciento founded?
ProSciento was founded in 2003. It employs 101 to 250 people.
Where is ProSciento based?
ProSciento is headquartered in Chula Vista, United States, in the North America region.
How does ProSciento make money?
One revenue line is on record: clinical Research Services (CRO/CRD/PSS/CRI).
Who are ProSciento's main competitors?
ICON plc is listed as an others. Direct peers are Medpace, Profil Institut für Stoffwechselforschung, Celerion, Worldwide Clinical Trials, QPS Holdings and Biotrial. Broad incumbents are IQVIA, Labcorp Drug Development (Fortrea) and Syneos Health.
Does ProSciento have an API?
No public API is recorded for ProSciento.
What industry is ProSciento in?
ProSciento's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54171 and its SIC code is 8731.